Royal Bank Of Canada Lowers Chemours (NYSE:CC) Price Target to $17.00

Chemours (NYSE:CC) had its price target lowered by equities research analysts at Royal Bank Of Canada from $19.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the specialty chemicals company’s stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 34.55% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Chemours from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. Truist Financial lifted their price target on shares of Chemours from $18.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. UBS Group increased their price objective on shares of Chemours from $17.00 to $21.00 and gave the company a “buy” rating in a report on Monday, October 6th. Mizuho cut their price objective on Chemours from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Thursday, October 16th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Chemours in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.50.

Chemours Price Performance

Shares of Chemours stock opened at $12.64 on Monday. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -5.69 and a beta of 1.64. The company has a quick ratio of 0.88, a current ratio of 1.71 and a debt-to-equity ratio of 13.66. The stock’s 50-day simple moving average is $14.77 and its 200-day simple moving average is $13.25. Chemours has a 52 week low of $9.13 and a 52 week high of $22.38.

Chemours (NYSE:CC) last issued its earnings results on Thursday, November 6th. The specialty chemicals company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.04). Chemours had a negative net margin of 5.70% and a positive return on equity of 35.27%. The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period last year, the business posted $0.40 EPS. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. Chemours has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that Chemours will post 2.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Chemours

Several institutional investors have recently modified their holdings of CC. Millennium Management LLC increased its position in shares of Chemours by 60.4% during the 1st quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company’s stock valued at $54,428,000 after purchasing an additional 1,515,520 shares during the last quarter. Scopia Capital Management LP boosted its stake in Chemours by 71.7% during the second quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company’s stock worth $38,418,000 after buying an additional 1,401,539 shares during the period. Vanguard Group Inc. boosted its stake in Chemours by 8.3% during the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company’s stock worth $223,069,000 after buying an additional 1,263,047 shares during the period. State Street Corp increased its position in Chemours by 22.7% during the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock valued at $70,009,000 after acquiring an additional 1,131,682 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Chemours by 41.4% in the second quarter. Geode Capital Management LLC now owns 3,484,416 shares of the specialty chemicals company’s stock valued at $39,901,000 after acquiring an additional 1,020,933 shares during the period. 76.26% of the stock is owned by institutional investors.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.